British Prime Minister Rishi Sunak has links to a Pharmaceuticals company that only has one product - Covid-19 'Vaccine'.
Sunak invested heavily in a Moderna, one of the Pharmaceutical companies who created the Covid MRNA 'vaccine', their first, and only product. His involvement in the company was reported in the Guardian in 2020 whilst he was still Britain's Chancellor, but has come under renewed scrutiny as more questions about Moderna emerge.
News that he has links to the pharmaceuticals giant comes after it was revealed that he also has links to the World Economic Forum's Social Credit Score system, with his father-in-law owning the company producing its surveillance software.
Moderna, is one of the biggest investments held by the hedge fund Rishi Sunak co-founded before entering parliament. Sunak was a founding partner of Theleme Partners, a major investor in Moderna, and one of the executives managing its US office.
The day after Moderna claimed its trials were successful (94.5% effective) Matt Hancock, the then Health Secretary stated that the UK government had secured an advance order for 5m doses of their 'vaccine'. Moderna, a company that has now provided tens of millions of Covid' vaccine' doses were unheard of prior to 2020.
Rishi Sunak's Hedge Fund is reported to have invested in Moderna before the company was listed on the Nasdaq stock exchange in 2018.
The pharmaceuticals company's only commercial product is the Moderna COVID-19 'vaccine'. Moderna formed in 2018 to take advantage of the mRNA technology it's Stanford founders had created. In July of 2018, the company opened a 200,000 square foot facility in Norwood, Massachusetts for manufacturing, preclinical and clinical work.
In May 2019, the company together with Merck Sharp & Dohme, entered a Phase I clinical trial for mRNA-5671 vaccine in combination with pembrolizumab for the treatment of solid tumors with driver mutations in the KRAS gene.[31]
On the 12th December 2019 (some 19 Days BEFORE the supposed discovery of Covid-19) Moderna provided an ‘mRNA coronavirus vaccine candidate’ developed jointly by NIAID and Moderna, to The University of North Carolina for evaluation.
'In it up to his neck'
Related:
Comments